Trailing Twelve Months Revenue Growth: surrozen.com (SRZN)

The year-over-year sales trajectory over a rolling four quarters from the GURU.Markets service demonstrates the capitalization of Surrozen, Inc. (SRZN) patents in the field of tissue regeneration. The value 193.00 captures this metric while the business relies on Wnt-pathway management for organ treatment. The company's fate depends on FDA approval and venture financing within the stem cell therapy niche.
Surrozen - analytical breakdowns and key metrics (SRZN)

Partner payments from pharma behemoths for access to the Wnt modeling platform drive the current rolling year-over-year revenue growth trend for Surrozen, Inc. (SRZN). This indicator assesses the fundamental stability of the business by neutralizing short-term market volatility. The calculation is based on comparing the current twelve-month sales total with the same period from the previous year. A slowdown in growth rates signals a risk of stagnation until new clinical data emerges. The asset is categorized as a high-risk speculative security.